Advancing Gene Therapy Research for Hemophilia A at MCW
Kristi Castello, Division Administrator III at the Medical College of Wisconsin, reposted from Medical College of Wisconsin on LinkedIn:
Quoting Medical College of Wisconsin‘s post:
”For people with hemophilia A, a simple cut or bump can cause excessive bleeding or bruising. While treatments exist to replace this protein, patients may form antibodies to the current therapies.
For more than two decades, MCW’s David A. Wilcox, PhD has worked with colleagues to develop a new gene therapy that could transform how patients with the disease are treated.
The team has completed preliminary studies of a Phase 1 clinical trial at MCW, ran by MCW’s Dr. Mary Eapen, with a gene therapy that genetically-modifies a patient’s own bone marrow cells to make a blood clotting factor.
Learn more:”

Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian